The Prmt3 Knockout Hepa 1-6 Cell Line is a CRISPR/Cas9-edited knockout cell line generated from the Hepa 1-6 murine hepatoma model, featuring targeted disruption of the protein arginine methyltransferase 3 (Prmt3) gene. As a ready-to-use cell-based model, it provides researchers with a stable loss-of-function system to investigate PRMT3’s enzymatic function in hepatocellular carcinoma. The knockout eliminates PRMT3-mediated asymmetric arginine dimethylation, allowing for precise phenotypic characterization in liver cancer contexts.
Hepa 1-6 is a well-characterized hepatocellular carcinoma cell line derived from the BW7756 tumor that arose spontaneously in a C57L/J mouse. These adherent, epithelial-like cells retain key features of malignant hepatocytes and are widely employed in cancer biology, tumor immunology, and preclinical drug testing. Their syngeneic compatibility with C57BL/6 mice facilitates in vivo tumor models, making them a gold standard for evaluating oncology drug candidates and studying tumor microenvironment interactions.
PRMT3 belongs to the protein arginine methyltransferase family and specifically catalyzes the monomethylation and asymmetric dimethylation of arginine residues on substrate proteins, most notably ribosomal protein S2 (RPS2). This methylation event, which consumes S-adenosylmethionine (SAM) as a methyl donor, is critical for ribosome biogenesis and efficient translation. PRMT3 activity is regulated by upstream signals including the MYC oncoprotein, mTORC1 kinase, and cellular stress pathways. Upon activation, PRMT3 interacts with ribosomal subunits and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to methylate RPS2, facilitating 40S ribosomal subunit assembly and modulating mRNA splicing. Downstream consequences of PRMT3 activity include altered ribosomal function and translational control, directly impacting protein synthesis.
In the context of hepatocellular carcinoma, PRMT3-mediated methylation is thought to drive oncogenic processes by sustaining elevated protein synthesis required for rapid proliferation. CRISPR/Cas9-mediated disruption of Prmt3 in Hepa 1-6 cells eliminates RPS2 asymmetric dimethylation, potentially crippling ribosome assembly and attenuating global translation. Given that mTOR signaling is often hyperactivated in liver cancer, examining PRMT3 deficiency in these cells provides insight into the intersection between arginine methylation and growth-factor-driven translational reprogramming. Additionally, the syngeneic nature of Hepa 1-6 allows for in vivo evaluation of PRMT3’s role in tumorigenesis and metastasis in immunocompetent hosts.
This knockout cell line is a versatile tool for investigating PRMT3 function in hepatocellular carcinoma, ribosome biogenesis, translational regulation, and mRNA splicing. Researchers can employ a variety of assays, including western blotting for asymmetric dimethylarginine (aDMA), RPS2 methylation assays, polysome profiling to assess ribosome assembly, cell proliferation assays (MTT, BrdU), RNA sequencing for splicing analysis, flow cytometric cell cycle profiling, and in vivo tumor xenograft studies. The model also supports drug target validation and analysis of methylation-dependent signaling pathways. For technical inquiries or to obtain a quotation, please contact Ascent Research.
